Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Neoplasma Vol.52, p.393-397, 2005 |
||
Title: Posttreatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer | ||
Author: D., FELTL ; E., ZAVADOVA ; M., PALA ; P., HOZAK ; | ||
Abstract: Between 2001 and 2002, 29 patients with advanced inoperable
squamous head and neck cancer treated with radiotherapy
with or without simultaneous chemotherapy were evaluated for their
plasma TGF-ß1 levels prior to the treatment, in the
middle of the radiotherapy course and at the end of the treatment.
Patients were assessed for treatment response and late
morbidity. Predictive value of TGF-ß1 level on either of the
assessed parameters was tested. From 29 eligible patients (pts), 18 achieved complete response, 8 partial response and three pts progressed primarily. After a median follow-up of 16 months we recorded 16 cases of grade >1 late morbidity. We found that posttreatment elevated plasma TGF-ß1 level predicts late morbidity grade >1 (p=0.05) rather than pretreatment level (p=0.062). Neither pretreatment nor posttreatment plasma TGF-ß1 level has a predictive value to the treatment response (CR vs. no CR, p=0.125 and 0.252, respectively). The posttreatment plasma TGF-beta 1 level can predict late morbidity grade >1 in advanced head and neck cancer treated with radio(chemo)therapy. This could make a basis for dose escalation in selected patients. |
||
Keywords: head and neck cancer, late morbidity, radiotherapy, TGF-beta1 | ||
Year: 2005, Volume: 52, Issue: | Page From: 393, Page To: 397 | |
|
download file |
|